Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab biosimilar - Sandoz

Drug Profile

Rituximab biosimilar - Sandoz

Alternative Names: GP-2013; Rixathon; Riximyo; SDZ-RTX

Latest Information Update: 24 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sandoz
  • Developer Kyowa Kirin; Sandoz; University of Leeds
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Granulomatosis with polyangiitis; Idiopathic thrombocytopenic purpura; Lymphoproliferative disorders; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Thrombotic thrombocytopenic purpura
  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 18 Nov 2020 Launched for Thrombotic thrombocytopenic purpura in Japan (IV)
  • 18 Nov 2020 Registered for Thrombotic thrombocytopenic purpura in Japan (IV)
  • 17 Nov 2020 Preregistration for Thrombotic thrombocytopenic purpura in Japan (IV), prior to November 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top